Beyond Cancer: CAR-T Therapy Expands into Non-Oncological Diseases

Published on LinkedIn via Spencer Knight

CAR-T cell therapy, originally developed for cancer, is now advancing into non-oncological areas including autoimmune diseases, fibrosis, infections, haemophilia, and aging. Dual-targeting CARs such as CD19‑BCMA are showing strong promise in conditions like lupus, where conventional treatments often fail. This growing versatility highlights how engineered immune cells may soon become central tools in treating a much broader range of diseases.

Read the full article on LinkedIn:

👉 CAR T Therapy in Non-Oncology

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.